Cinpanemab

Cinpanemab
Monoclonal antibody
Type?
Targetα-Synuclein
Clinical data
Other namesBIIB054; BIIB-054; NI-202; NI202
Identifiers
CAS Number
DrugBank
UNII

Cinpanemab (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names BIIB054, NI-202) is an anti-α-synuclein drug acting as a monoclonal antibody against α-synuclein which was under development for the treatment of Parkinson's disease. It showed no significant influence on disease progression in a 52-week phase 2 clinical trial. The drug reached phase 2 clinical trials but was discontinued in 2021 due its lack of effectiveness. It was under development by Biogen.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.